Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Pericentrin deficiency in smooth muscle cells augments atherosclerosis through HSF1-driven cholesterol biosynthesis and PERK activation
Suravi Majumder, Abhijnan Chattopadhyay, Jamie M. Wright, Pujun Guan, L. Maximilian Buja, Callie S. Kwartler, Dianna M. Milewicz
Suravi Majumder, Abhijnan Chattopadhyay, Jamie M. Wright, Pujun Guan, L. Maximilian Buja, Callie S. Kwartler, Dianna M. Milewicz
View: Text | PDF
Research Article Genetics Vascular biology

Pericentrin deficiency in smooth muscle cells augments atherosclerosis through HSF1-driven cholesterol biosynthesis and PERK activation

  • Text
  • PDF
Abstract

Microcephalic osteodysplastic primordial dwarfism type II (MOPDII) is caused by biallelic loss-of-function variants in pericentrin (PCNT), and premature coronary artery disease (CAD) is a complication of the syndrome. Histopathology of coronary arteries from patients with MOPDII who died of CAD in their 20s showed extensive atherosclerosis. Hyperlipidemic mice with smooth muscle cell–specific (SMC-specific) Pcnt deficiency (PcntSMC–/–) exhibited significantly greater atherosclerotic plaque burden compared with similarly treated littermate controls despite similar serum lipid levels. Loss of PCNT in SMCs induced activation of heat shock factor 1 (HSF1) and consequently upregulated the expression and activity of HMG-CoA reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis. The increased cholesterol biosynthesis in PcntSMC–/– SMCs augmented PERK signaling and phenotypic modulation compared with control SMCs. Treatment with the HMGCR inhibitor, pravastatin, blocked the augmented SMC modulation and reduced plaque burden in hyperlipidemic PcntSMC–/– mice to that of control mice. These data support the notion that Pcnt deficiency activates cellular stress to increase SMC modulation and plaque burden, and targeting this pathway with statins in patients with MOPDII has the potential to reduce CAD in these individuals. The molecular mechanism uncovered further emphasizes SMC cytosolic stress and HSF1 activation as a pathway driving atherosclerotic plaque formation independently of cholesterol levels.

Authors

Suravi Majumder, Abhijnan Chattopadhyay, Jamie M. Wright, Pujun Guan, L. Maximilian Buja, Callie S. Kwartler, Dianna M. Milewicz

×

Figure 4

Augmented phenotypic modulation of PcntSMC–/– SMCs is due to increased HSF1 activation driving cholesterol biosynthesis.

Options: View larger image (or click on image) Download as PowerPoint
Augmented phenotypic modulation of PcntSMC–/– SMCs is due to increased H...
(A) Augmented SMC phenotypic modulation in PcntSMC–/– SMCs is evident from decreased mRNA expression of Cnn1 and increased mRNA expression of modulation markers Lgals3, Fn1, Serpine1, and Ly6a either at baseline or with exposure to 2.5 μg/mL MBD-Chol in PcntSMC–/– SMCs, compared with 10 μg/mL MBD-Chol in WT SMCs, while Vcam1 expression increases in both genotypes only with 10 μg/mL MBD-Chol. (B) PcntSMC–/– SMCs show increased migration by Transwell migration assay at baseline and with cholesterol exposure. (C) PcntSMC–/– SMCs exhibit increased levels of total and phosphorylated HSF1 (p-HSF1) at baseline. (D) HSF1 mRNA expression and luciferase activity and expression of HSF1 downstream targets Hspa1a, Hsp90aa1, and Hsp90ab1 are also upregulated at baseline in PcntSMC–/– SMCs (all data in A–D passed normality and were analyzed by 2-way ANOVA followed by Tukey’s multiple-comparison test, except HSF1 activity, which was analyzed by Kruskal-Wallis test). (E–G) Hmgcr expression was significantly elevated in PcntSMC–/– SMCs (E), along with HMGCR enzymatic activity (F) and cholesteryl ester levels (G; data in E–G were analyzed by unpaired, 2-tailed Student’s t test followed by Welch’s correction). All gene expression data are representative of 3 independent experiments. Error bars represent SD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. CE, cholesteryl esters.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts